Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Chimeric antigen receptor T-cell therapy improves not only lupus disease activity but also other related conditions that ...

CAR-T cell therapy involves extracting a patient's T-cells, modifying them to recognize cancer cells, and then reinfusing them into the patient where they target cancer cells throughout the body.

A cancer therapy that uses genetically engineered immune cells, called CAR T-cells, has kept a person free of a potentially fatal nerve tumour for a record-breaking 18 years. “This is ...

In part 2 of this interview with Frederick L. Locke, MD, lead investigator on the phase 1 ALPHA (NCT03939026) and ALPHA2 (NCT04416984) trials of allogeneic chimeric antigen receptor T-cell therapy ...

Biosciences announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease ...

The CAR T-cell therapy market size was valued at $2.6 billion in 2022 & is estimated to hit $35.9 billion by 2032, exhibiting a CAGR of 28 ...

IN8bio (INAB) unveiled INB-600, its next generation gammadelta T cell-based TCE platform. It is designed to address one of the biggest ...